AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pancreatic Cancer Genetic Epidemiology (PACGENE) Study

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-09-10

Last Posted Date: 2020-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4770

Registration Number: NCT00526578

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Phase 1

Completed

Conditions: Gastrointestinal Diseases

Interventions: Drug: 5-Fluorouracil
Drug: Docetaxel
Drug: Oxaliplatin

First Posted Date: 2007-09-06

Last Posted Date: 2016-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00526110

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brachytherapy for Prostatic Carcinoma Patients

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Brachytherapy
Behavioral: Questionnaire

First Posted Date: 2007-09-06

Last Posted Date: 2025-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 300

Registration Number: NCT00525720

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

Phase 2

Completed

Conditions: Stomach Cancer
Gastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Folinic Acid
Drug: Oxaliplatin
Radiation: Radiotherapy
Procedure: Surgery

First Posted Date: 2007-09-06

Last Posted Date: 2020-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00525785

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cancer Genetics CD-ROM for Hispanics

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Focus Group
Behavioral: Computer Program
Other: Written Materials
Behavioral: Questionnaires

First Posted Date: 2007-09-06

Last Posted Date: 2013-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00525980

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The Cancer and Chronic Disease Consortium (CCDC) of El Paso, El Paso, Texas, United States

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Alemtuzumab
Drug: Rituximab

First Posted Date: 2007-09-06

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00525603

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

Completed

Conditions: Skin Cancer

Interventions: Procedure: OIR Imaging

First Posted Date: 2007-09-06

Last Posted Date: 2012-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 490

Registration Number: NCT00526032

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Non-Myeloablative Allogeneic Stem Cell Transplantation

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
Procedure: Allogeneic Stem Cell Infusion
Drug: Alemtuzumab

First Posted Date: 2007-09-06

Last Posted Date: 2011-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00525876

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

Phase 2

Completed

Conditions: Esophageal Cancer
Gastroesophageal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Surgery

First Posted Date: 2007-09-06

Last Posted Date: 2015-02-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 126

Registration Number: NCT00525915

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)

Not Applicable

Completed

Conditions: Colorectal Cancer
Familial Adenomatous Polyposis

Interventions: Behavioral: Web-Based Multimedia Intervention
Behavioral: Questionnaire

First Posted Date: 2007-09-06

Last Posted Date: 2021-03-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00525655

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy